Explore
Urological Cancer 2022
0 Ungluers have
Faved this Work
Login to Fave
In the urological sphere, the number of tumor malignancies caused by cancer is continuously growing in Western countries. Although this is mainly due to the contemporary increase in the life expectancy of people in these geographic areas, many other factors are also contributing to this growth. Urological cancer is a complex and varied disease which affects different organs and mainly affects the male population. In fact, in most statistics, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males. The female population, however, has also been increasingly affected by renal and bladder cancer in the last decade. From these facts, it is clear that urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light on the complexity of this field and will consider all useful and appropriate contributions from scientists and clinicians in order to improve urological cancer knowledge for patients’ benefit.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 29 times via unglue.it ebook links.
- 29 - pdf (CC BY) at Unglue.it.
Keywords
- 22Rv1
- activin
- androgen receptor axis
- biomarker
- bisphenol A
- bisphenol S
- Bladder cancer
- cancer genome
- CAPRA-S
- carbon-ion radiotherapy
- castration resistance
- castration resistant
- castration sensitive
- Charlson Comorbidity Index
- clear cell renal cell carcinoma
- Clinical & internal medicine
- CNTF
- CNTFRα
- Consolidated Framework for Implementation Research
- Diagnosis
- Diseases & disorders
- E-MTAB-1980
- early survival
- elderly patients
- Energy Metabolism
- ERK
- everolimus
- false-positive results
- ferroptosis
- follow-up care
- general practice
- Gleason grade
- GLS2
- high-risk prostate cancer
- Immunotherapy
- indocyanine green
- INHBA
- INHBB
- INHBC
- Life expectancy
- LNCaP
- male incontinence
- medicine
- migration
- MMP
- multiparametric magnetic-resonance imaging
- n/a
- nephron sparing
- neuroendocrine carcinoma
- Nivolumab
- non-interventional study
- oncology
- PARP inhibition
- particle beam therapy
- pazopanib
- PET scan
- precision targeting
- primary diagnosis
- Primary Health Care
- process evaluation
- prognostic model
- proliferation
- prostate cancer
- prostate cancer survivors
- prostate-specific antigen
- prostate-specific membrane antigen positron-emission tomography
- PSA
- PSMA
- Radiotherapy
- real world-data
- real-world data
- renal cell carcinoma
- robot-assisted partial nephrectomy
- robotic prostatectomy
- STAT3
- systematic review
- systemic immune-inflammation index
- TCGA
- time on drug
- transforming growth factor-β family
- trial-eligibility
- tumor
- ureteral neoplasms
- ureteroscopy
- urinary bladder neoplasms
Links
DOI: 10.3390/books978-3-0365-6969-7Editions